Inflammatory conditions on the skin or in the eyes may negatively affect the appearance and quality of life, why patients are highly involved in the choice of therapy. Topical therapies need to provide the three essentials in a single product: (i) high efficacy; (ii) high tolerability and (iii) high adherence (patient preference).
Topical therapies may be difficult to develop for reasons of stability or solubility of the active ingredients or due to difficulties in delivering active ingredients into the target tissue through the barrier of the skin or the eyes. This often results in compromised formulations that do not release the full potential of the active ingredients or that people do not like to use in daily routines, e.g. because they are greasy (stain clothes and bedding) or causes stinging and burning. Inferior topical formulations amplify discontinuation of therapy, dissatisfaction and shifting to other topicals or much more expensive systemic therapies (orals or biologics).
PAD™ Technology enables new topical formulations of potent active ingredients tailored to be highly efficacious and tolerable and pleasant to use in daily routines. This enables topical formulations of novel active ingredients and an opportunity to significantly upgrade existing leading topical drugs. PAD™ Technology enables a new standard in topical therapies for autoimmune and inflammatory conditions.
Our current pipeline includes PAD™ based drug candidates as well as biomee™ – a novel skin care line designed for dry, itchy and sensitive skin.
Our pipeline and products are addressing major diseases such as psoriasis, atopic dermatitis, uremic pruritus, lichen sclerosus and dry eyes: